食管腺癌新辅助放化疗后淋巴结反应的重要性
本研究评估193例临床怀疑淋巴结阳性(cN+)的食管腺癌患者在接受新辅助放化疗(nCRT)后的淋巴结反应(LNR)对预后的价值。根据病理分为ypN0/LNR-、ypN0/LNR+和ypN+三组,并与188例直接手术的cN+患者比较。结果显示ypN0/LNR-组中位总生存期达96.4个月,显著优于ypN0/LNR+组的31.2个月,且与直接手术pN0组(104.2个月)相当;ypN+组与pN+组生存无差异。提示部分nCRT后ypN0患者可能本身即为真正N0,存在过度治疗。
要点
- cN+食管腺癌nCRT后ypN0/LNR-患者中位OS达96.4个月,与直接手术pN0相当。
- ypN0/LNR+患者中位OS仅31.2个月,死亡风险是LNR-患者的3倍。
- ypN+患者与直接手术pN+患者生存无差异,nCRT未带来额外获益。
核心结论
- 在cN+食管腺癌患者中,nCRT后ypN0且无LNR迹象者中位OS为96.4个月,与直接手术pN0者相当,提示约23%的nCRT患者可能为真正N0而过度治疗。
- ypN+患者与直接手术pN+患者生存无差异,nCRT未改善该组预后。
研究设计与样本
- 回顾性评估193例2008-2015年接受nCRT的cN+食管腺癌患者的H&E切片,根据有无存活肿瘤细胞定义ypN状态及LNR,并与188例直接手术的cN+患者比较。
关键数值与推荐
- 淋巴结含存活肿瘤细胞定义为ypN+,无存活肿瘤细胞定义为ypN0;LNR按既往定义方法描述。
临床怎么用
- nCRT后ypN0且LNR-的患者可能为真正N0,预后良好,需反思nCRT的必要性以避免过度治疗。
- ypN0但LNR+的患者预后较差,死亡风险为LNR-者的3倍,应加强术后随访或辅助治疗。
- ypN+患者生存与直接手术pN+相似,提示nCRT对该组获益有限。
局限性
- 回顾性研究,样本量有限,LNR定义基于既往方法,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor response and lymph node involvement are the most important prognosticators in resected patients with esophageal adenocarcinoma after neoadjuvant chemoradiotherapy (nCRT). We hypothesize that lymph node response (LNR) is also a valuable prognosticator in these patients, potentially revealing the added effect of nCRT. METHODS: Hematoxylin and eosin slides of 193 esophageal adenocarcinoma patients with clinical suspicion of lymph node involvement (cN+) and treated with nCRT between 2008 and 2015 were assessed. Lymph nodes containing viable tumor cells were considered ypN+, and those negative for viable tumor were ypN0. LNR was also described according to an earlier defined method. Three groups were obtained: ypN0/LNR-, ypN0/LNR+, and ypN+. They were compared with 188 cN+ patients being pN0 (n = 45) or pN+ (n = 143) after upfront esophageal resection. RESULTS: Forty-four patients were ypN0/LNR-, 55 were ypN0/LNR+, and 94 were ypN+. Median overall survival was 96.4, 31.2, and 20.6 months, respectively, and was significantly different between ypN0/LNR- and ypN0/LNR+ groups (P = .020). Survival was comparable between ypN0/LNR- and pN0 (104.2 months) groups (P = .519) and between ypN+ and pN+ (21.6 months) groups (P = .966). In ypN0 patients, risk of death in LNR+ patients was tripled compared with LNR- patients. CONCLUSIONS: In cN+ esophageal adenocarcinoma patients treated with nCRT with postoperative final pathology being ypN0, median overall survival is tripled when no signs of LNR were found and comparable to cN+/pN0 upfront esophagectomy patients, suggesting that 23% of patients treated with nCRT were in fact true N0 and overtreated by nCRT. ypN+ patients have no survival benefit compared with pN+ patients.
引用
- Depypere L, De Hertogh G, Moons J, et al. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. Ann Thorac Surg. 2020. PMID: 33352178. doi:10.1016/j.athoracsur.2020.09.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。